Focus research 2022 MELASPHINX team

Discovery of new biomarkers of resistance to melanoma immunotherapies

The team showed that neutralization of TNFα, a major inflammatory cytokine, potentiates the response to anti-PD-1 in murine models of melanoma. This work underpins the scientific rationale for the TICIMEL clinical trial (NTC03293784), which aims to evaluate the safety, tolerability and anti-tumor activity of anti-TNFα molecules (certolizumab or infliximab) in combination with ipilimumab and nivolumab in patients with advanced melanoma. Initial results are promising, with signs of activation and maturation of the immune response, fewer side effects in patients treated with infliximab, and to date a better clinical response rate in the certolizumab-treated cohort. Investigations are ongoing in an expansion cohort.

To find out more about the IUCT-Oncopole and CRCT-Oncopole research focuses, please click here